Skip to main content
IDWeek 2021 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
View Session ViewAttendees 31

Adult ID

Investigative ID

Pediatric ID

Trainee

Transplant
Symposium

123 - ID Complications associated with Novel Cellular & Immunotherapies in Cancer

Saturday, October 2, 2021
10:00 AM - 11:15 AM EDT

    Moderator(s)

  • Jay Fishman, MD

    Professor of Medicine, Director Transplant Infectious Disease
    Massachusetts General Hospital - Harvard Medical School
    Boston, MA, United States

    I do not have any relevant financial / non-financial relationships with any proprietary interests.

  • Pearlie Chong, MD, MSCR

    Assistant Professor of Medicine
    University of Texas Southwestern
    Dallas, TX, United States

    I do not have any relevant financial / non-financial relationships with any proprietary interests.

    • Speaker(s)

  • Mark Lustberg, MD, PhD

    Medical School Recruit (for Associate Professor)
    Infectious Diseases
    Yale School of Medicine
    New Haven, Connecticut, United States

    I do not have any relevant financial / non-financial relationships with any proprietary interests.

  • Joshua Hill, MD

    Assistant Professor
    Fred Hutchinson Cancer Center
    Seattle, Washington, United States

    Allogene (Individual(s) Involved: Self): Consultant; Allovir (Individual(s) Involved: Self): Consultant, Grant/Research Support; Amplyx (Individual(s) Involved: Self): Consultant; Covance/CSL (Individual(s) Involved: Self): Consultant; CRISPR (Individual(s) Involved: Self): Consultant; Gilead (Individual(s) Involved: Self): Consultant, Grant/Research Support; Karius: Grant/Research Support, Scientific Research Study Investigator; Medscape (Individual(s) Involved: Self): Consultant; Octapharma (Individual(s) Involved: Self): Consultant; OptumHealth (Individual(s) Involved: Self): Consultant; Takeda (Individual(s) Involved: Self): Consultant, Grant/Research Support, Scientific Research Study Investigator

  • Nirali Shah, MD

    Lasker Clinical Research Scholar
    National Institutes of Health
    Bethesda, MD, United States

    I do not have any relevant financial / non-financial relationships with any proprietary interests.

Participants should be aware of the following financial/non-financial relationships:
Jay A. Fishman, MD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Pearlie P. Chong, MD, MSCR: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Mark E. Lustberg, MD, PhD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Joshua A. Hill, MD: Allogene (Individual(s) Involved: Self): Consultant; Allovir (Individual(s) Involved: Self): Consultant, Grant/Research Support; Amplyx (Individual(s) Involved: Self): Consultant; Covance/CSL (Individual(s) Involved: Self): Consultant; CRISPR (Individual(s) Involved: Self): Consultant; Gilead (Individual(s) Involved: Self): Consultant, Grant/Research Support; Karius: Grant/Research Support, Scientific Research Study Investigator; Medscape (Individual(s) Involved: Self): Consultant; Octapharma (Individual(s) Involved: Self): Consultant; OptumHealth (Individual(s) Involved: Self): Consultant; Takeda (Individual(s) Involved: Self): Consultant, Grant/Research Support, Scientific Research Study Investigator
Nirali N. Shah, MD: I do not have any relevant financial / non-financial relationships with any proprietary interests.

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
ACPE Credits: ACPE 1.25 Knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-0000-21-001-H01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:
  • discuss acute cytokine release syndrome, non-infectious treatment complications, and immunologic shifts post treatment
  • describe common infections among patients undergoing CAR-T cell therapy, prophylaxis and prevention strategies. Include discussion of acute cytokine release syndrome and vaccination post-treatmen
  • review the emerging epidemiology of infections in novel immunotherapeutic and molecular targeted agents in hematologic malignancy

Presentations:

  • Infections in Cancer Patients Receiving Novel Immunotherapeutic and Molecular Targeted Agents

    Speaker: Mark E. Lustberg, MD, PhD – Yale School of Medicine

  • Infectious Complications of CD19-targeted Chimeric Antigen Receptor-modified T (CAR-T)-cell Immunotherapy

    Speaker: Joshua A. Hill, MD – Fred Hutchinson Cancer Research Center; University of Washington

  • Novel Cellular and Immunotherapies: How Do They Work and What Are Their Effects on Immunity?

    Speaker: Nirali N. Shah, MD – National Institutes of Health